Janux Therapeutics (NASDAQ:JANX) Stock Price Down 4.6%

Janux Therapeutics, Inc. (NASDAQ:JANX) fell 4.6% on Tuesday . The company traded as low as $39.22 and last traded at $39.79. 245,485 shares changed hands during trading, a decline of 69% from the average session volume of 802,316 shares. The stock had previously closed at $41.72.

Analyst Ratings Changes

A number of brokerages have weighed in on JANX. Jonestrading assumed coverage on Janux Therapeutics in a research report on Tuesday, April 16th. They set a “buy” rating and a $70.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a report on Thursday, May 9th. Wedbush boosted their price objective on Janux Therapeutics from $53.00 to $74.00 and gave the stock an “outperform” rating in a report on Wednesday, May 8th. Scotiabank assumed coverage on Janux Therapeutics in a report on Thursday, May 30th. They set a “sector perform” rating and a $47.00 price objective for the company. Finally, Bank of America boosted their price objective on Janux Therapeutics from $24.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, March 13th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Janux Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.29.

Janux Therapeutics Stock Down 5.8 %

The firm has a market capitalization of $2.04 billion, a P/E ratio of -33.14 and a beta of 3.58. The firm has a 50 day moving average of $47.65 and a 200-day moving average of $32.38.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.05. Janux Therapeutics had a negative return on equity of 13.49% and a negative net margin of 762.92%. The business had revenue of $1.25 million during the quarter, compared to analysts’ expectations of $0.98 million. As a group, research analysts expect that Janux Therapeutics, Inc. will post -1.34 EPS for the current year.

Insider Transactions at Janux Therapeutics

In other news, CFO Tighe Reardon sold 822,721 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $54.75, for a total transaction of $45,043,974.75. Following the completion of the transaction, the chief financial officer now directly owns 633,673 shares in the company, valued at $34,693,596.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Tighe Reardon sold 822,721 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total value of $45,043,974.75. Following the completion of the sale, the chief financial officer now directly owns 633,673 shares in the company, valued at $34,693,596.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jay Lichter sold 1,500,000 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $54.75, for a total value of $82,125,000.00. Following the completion of the sale, the director now owns 633,673 shares of the company’s stock, valued at $34,693,596.75. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,000,000 shares of company stock worth $164,250,000. Corporate insiders own 35.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC increased its holdings in Janux Therapeutics by 2,166.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 26,264 shares of the company’s stock valued at $282,000 after purchasing an additional 25,105 shares during the period. Cerity Partners LLC acquired a new stake in Janux Therapeutics during the 4th quarter worth about $654,000. China Universal Asset Management Co. Ltd. acquired a new stake in Janux Therapeutics during the 4th quarter worth about $57,000. Swiss National Bank grew its holdings in Janux Therapeutics by 39.5% during the 4th quarter. Swiss National Bank now owns 31,800 shares of the company’s stock worth $341,000 after acquiring an additional 9,000 shares during the period. Finally, Adage Capital Partners GP L.L.C. grew its holdings in Janux Therapeutics by 27.8% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company’s stock worth $11,592,000 after acquiring an additional 250,000 shares during the period. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.